- Home
- Miscellaneous
- China-developed COVID-19 mRNA vaccine as booster safe, immunogenic in clinical trial
China-developed COVID-19 MRNA Vaccine As Booster Safe, Immunogenic In Clinical Trial
Sumaira FH Published June 16, 2022 | 05:10 PM
BEIJING, (UrduPoint / Pakistan Point News - 16th Jun, 2022 ) :A China-developed mRNA COVID-19 vaccine as a third booster dose has been shown in human trials to be safe and able to induce an immune response against the Omicron variant.
AWcorna, previously known as ARCoV, which encodes the receptor-binding domain of SARS-CoV-2 spike protein, is now being tested in the final stage of multiple-center phase-3 trials.
In a randomization clinical trial, scientists from the academy of Military Medical Sciences in China, Guangzhou Institute of Respiratory Health, and Walvax Biotechnology Co., Ltd. enrolled 300 adults who have received a two-dose inactivated vaccination.
All participants were randomly assigned to either the AWcorna or inactivated vaccine booster group, and the neutralization and antibody titers in their bodies were assessed at pre-booster, 14- and 28-day post-booster, according to an article published online this week in the journal Cell Research.
AWcorna booster induced a 66-fold increase against wild-type SARS-CoV-2, and the neutralization antibody titers are over three times more than those in the inactivated vaccine group, according to the researchers.
Although the neutralization antibody titers against the Omicron variant showed a significant reduction compared with those against wild type in both groups, they maintained 28.1 at 28-days after the AWcorna booster, four times stronger than those in the inactivated vaccine group, which registered only 6.4.
The clinical results demonstrate that heterologous boosting with an mRNA vaccine could induce higher antibodies against the COVID-19 virus than a homologous booster, according to the researchers.
Also, no serious adverse events were reported in the AWcorna booster group.
The researchers said this vaccine booster's effectiveness in preventing COVID-19 infection remains to be determined, but its potent antibody induction supports the emergency use as a heterologous booster in China.
The ongoing international phase-3 trials with 28,000 participants will provide more about the safety profile of AWcorna, said the researchers.
Recent Stories
Currency Rate In Pakistan - Dollar, Euro, Pound, Riyal Rates On 7 May 2024
Today Gold Rate in Pakistan 07 May 2024
Sharjah Animation Conference explores cross-cultural collaboration opportunities ..
Sharjah Public Library provides countless opportunities for young imaginations t ..
Sharjah Police launches 'Your belongings, your responsibility' awareness campaig ..
Dubai Police displays Innovative Tourism Security Services at 'ATM 2024'
Mohammad Haris, Aamir Jamal not part of national squad for Ireland, England: Bab ..
Erdogan opens former church to Muslim worshippers
Cultural events hallmark of a nation, Director RAC
Iraq hangs 11 convicted of 'terrorism': security, health sources
Stocks rise on renewed hopes of rate cuts
PM assures all-out support to Saudi investment
More Stories From Miscellaneous
-
Concerted efforts urged to ease traffic flow on city roads
2 days ago -
Land degradation: A threat to food security
2 days ago -
Revamping health sector, a gigantic task ahead
2 days ago -
American band promotes intercultural harmony thru music fusions
3 days ago -
Waste Management – A persistent challenge for MWMC
4 days ago -
Experts for ending child labour
6 days ago
-
Labour Day - A reminder for better facilities to workers
6 days ago -
Stage Drama Mohabati Manhoon presents in Arts council Larkana
9 days ago -
Wheat farmers in a fix on price, procurement mechanism
9 days ago -
Modern tools to help transform crime investigation procedures
9 days ago -
Sanam Marvi captivates audience with mesmerizing performance
10 days ago -
Modern Education Techniques: A pathway to achieve economic development
11 days ago